Buy or sell ORIC Pharmaceuticals stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

ORIC Pharmaceuticals Stock

Biopharmaceutical company

Founded

2014

Notable Investors

Memorial Sloan - Kettering Cancer Center

Headquarters

South San Francisco CA, US

Total Funding

$178M

About ORIC Pharmaceuticals Stock

ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs. Relapsed patients lack further treatment options. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.

Investors

Funding History

November 2014$15.4M
November 2015$54.0M
February 2018$53.4M
August 2019$55.0M

Management

Chief Executive Officer

Jacob Chacko

Chief Scientific Officer

Lori Friedman

Chief Medical Officer

Pratik Multani

Chief Business Officer

Matthew Panuwat

Chief Financial Officer

Dominic Piscitelli

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from ORIC Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 150K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo